摘要
系统性红斑狼疮(SLE)是一种累及多系统多器官的炎症性自身免疫性疾病。已被广泛应用的类固醇激素及免疫抑制剂等药物虽然有效,但常有不同程度的副作用和不良反应。而对于重症难治性SLE,这些药物往往疗效不佳且不良反应严重。靶向性生物制剂的应用虽然显示出特定的疗效,展示出良好的应用前景,但迄今为止仅在不同自身抗体和信号通路等环节解决发病网络中的部分问题。因此临床上迫切需要一种更为行之有效的治疗方法。考虑到SLE的突出问题是人体免疫系统的障碍,且这些障碍复杂多变又难以控制,研究者希望从形成免疫系统的上游细胞中找到突破口。免疫细胞由干细胞分化而来,而干细胞是一类具有多向分化潜能和多种免疫调节功能的细胞,在向免疫细胞分化过程中有可能实现部分或全部免疫系统的修饰和重建。随着相关研究的不断深入,干细胞已逐步成功应用于SLE的治疗。
Systemic lupus erythematosus(SLE) is an inflammatory auto immune disease that affects multiple systems and organs. Corticosteroids and immunosuppressive drugs are widely used to treat patients with SLE, however, in the treatment of severe refractory SLE, these drugs are of limited value and have considerable adverse effects. Although the application of targeted drugs has shown specific efficacy and bright prospects, it has only solved a few problems involving autoantibodies and signaling pathways in the pathogenesis network. Therefore, it is highly desirable to find a more promising therapy. Considering that the prominent problem of SLE is human immune system disorder which is complex and difficult to be reversed, finding a breakthrough in the upstream cells of immune system is actable. Immunocytes are derived from stem cells, which have multiple differentiation potentials and immunoregulatory functions. It is possible to modify and reconstruct part or all of the immune system during the differentiation of stem cells to immune cells. With the development of related research, stem cells have been successfully applied to the treatment of SLE.
作者
李松珊
王晶莹
王梦蕾
林乃余
曾抗
LI Songshan;WANG Jingying;WANG Menglei;LIN Naiyu;ZENG Kang(Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China)
出处
《皮肤科学通报》
2018年第3期313-321,共9页
Dermatology Bulletin
关键词
造血干细胞
间充质干细胞
红斑狼疮
系统性
移植
Hematopoietic stem cells
Mesenchymal stem cells
Lupus erythematosus
systemic
Transplantation